Mein Warenkorb

VEGF-D

VEGF-D Molekülinformation

Englischer NameVascular endothelial growth factor DAnzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel2Target-AliasC-Fos Induced Growth Factor (Vascular Endothelial Growth Factor D),FIGF,c-Fos-induced growth factor,VEGFD,VEGF-D,Vascular Endothelial Growth Factor D
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameVascular endothelial growth factor D
Target-AliasC-Fos Induced Growth Factor (Vascular Endothelial Growth Factor D),FIGF,c-Fos-induced growth factor,VEGFD,VEGF-D,Vascular Endothelial Growth Factor D
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel2
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

VEGF-D Produktliste

  • Attribut

    Protein (5)

  • Produktbibliothek

    Online (5)

  • Spezies

    Human (2)Cynomolgus (1)Mouse (2)

  • Etikett

    His Tag (2)His Tag & Avi Tag (2)Fc Tag (1)

  • Marker

    Unconjugated (3)Biotin-labeled (2)

VEGF-D Molekülhintergrund

Vascular endothelial growth factor D (VEGF-D) is also known as C-fos induced growth factor (FIGF), which belongs to the PDGF / VEGF growth factor family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. This secreted protein VEGF-D / FIGF undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-2 and VEGFR-3. The structure and function of this protein is similar to those of VEGFC. FIGF / VEGF-D is highly expressed in lung, heart, small intestine and fetal lung. FIGF / VEGF-D may function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR / FLK1) and VEGFR-3 (FLT4) receptors.

VEGF-D Molekülalias

FIGF,VEGFD

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
EG-016EG-016; Ad-VEGF-APhase 2 ClinicalArk Therapeutics LtdPeripheral Vascular Diseases
Details
EG-011EG-011; Ad-VEGF-DPhase 2 ClinicalArk Therapeutics LtdAngina Pectoris
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns